Metastatic carcinoma of the urinary bladder in a 67-year-old female with underlying triple primary cancers  by Hung, Chia-Yen et al.
lable at ScienceDirect
Journal of Cancer Research and Practice 3 (2016) 49e53Contents lists avaiJournal of Cancer Research and Practice
journal homepage: http: / /www.journals .elsevier .com/journal-of-cancer-
research-and-pract iceCase reportMetastatic carcinoma of the urinary bladder in a 67-year-old female
with underlying triple primary cancers
Chia-Yen Hung a, Shir-Hwa Ueng b, Yung-Chang Lin a, Wen-Chi Chou a, *
a Division of Hematology and Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou and Chang Gung University School of
Medicine, Taoyuan, Taiwan
b Department of Pathology, Chang Gung Memorial Hospital at Linkou and Chang Gung University School of Medicine, Taoyuan, Taiwana r t i c l e i n f o
Article history:
Received 7 July 2015
Accepted 3 September 2015
Available online 21 March 2016
Keywords:
Multiple primary cancers
Signet ring cell carcinoma
Invasive lobular carcinoma
Metastatic urinary bladder cancer* Corresponding author. Division of Hematology a
Internal Medicine, Chang Gung Memorial Hospital
University School of Medicine, No. 5, Fuxing Road,
Taiwan.
E-mail address: wenchi3992@yahoo.com.tw (W.-C
Peer review under responsibility of The Chinese O
http://dx.doi.org/10.1016/j.jcrpr.2015.09.002
2311-3006/Copyright © 2016, The Chinese Oncology
creativecommons.org/licenses/by-nc-nd/4.0/).a b s t r a c t
Due to progressive ageing of our population and increasing cancer incidence rates, more and more pa-
tients are presenting with multiple primary cancers. Here we describe a case of metastatic carcinoma
involving the urinary bladder with underlying triple primary adenocarcinoma in a female adult.
A 67-year-old Taiwanese female presented to our institution in November 1997 with gastric signet
ring cell carcinoma, pT2N0M0, status post subtotal gastrectomy. In February 2003 she was diagnosed
with left breast invasive lobular carcinoma status post modiﬁed radical mastectomy, pT2N2M0.
Further examination in January 2005 revealed proximal transverse colon cancer, Dukes' C2, with
status post right hemicolectomy. She achieved disease-free status from all three malignancies after
surgical resection and adjuvant chemotherapy for breast and colon cancers sequentially. In
November 2011, she complained about sudden onset of gross hematuria for several days. Diagnostic
cystoscopy showed a mass lesion over her urinary bladder. Cystoscope-assisted biopsy showed
metastatic poorly differentiated adenocarcinoma with signet ring appearance. Herein we have dis-
cussed the pathologic role in the diagnosis of metastatic tumor involving a patient with multiple
primary cancers. We also explored the epidemiologic risk and potential causal mechanism of patients
with multiple primary cancers.
Copyright © 2016, The Chinese Oncology Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The term “Multiple primary neoplasm (MPN)” was ﬁrst docu-
mented by Billroth et al in 1889. Recently, a trend towards an in-
crease prevalence rate of MPN was noted and probably due to
improved treatment results and prognosis of various cancers.1
Additionally, early tumor detection through an elevated fre-
quency of cancer screening also may impact this increased diag-
nosis of MPN.1 Based on the Surveillance Epidemiology and End
Results (SEER) data between 1973 and 2000, cancer survivors had a
14% higher risk of developing a newmalignancy, and an heightenednd Oncology, Department of
at Linkou and Chang Gung
Guishin Town, Taoyuan 333,
. Chou).
ncology Society.
Society. Production and hosting byabsolute risk of 21 cancer cases per 10,000 person-years than the
general population.1
MPN has been identiﬁed in those cases harboring multiple tu-
mors that meet the criteria byWarren and Gates as follows: 1) Each
neoplasm must be malignant arising from histological evaluation;
2) Each neoplasmmust be anatomically separate and distinct. If the
intervening mucosa demonstrates dysplasia, it must be considered
as a multicentric primary lesion and not as two separate neo-
plasms; and 3) The possibility that the second neoplasm represents
a metastasis should be excluded.2 However, the differentiation of
second primary cancer from metastasis is still arguable mainly
under the assistance of distance, diagnosis time difference or even
molecular analysis of different tumors.3e5
Cases involving more than two primary malignant neoplasms
are very rare. In this report, we present the case of a female patient
with metastatic carcinoma of the urinary bladder from metachro-
nous triple primary malignant neoplasms of: 1) the stomach ﬁrst,
2) then the left breast, and then 3) the transverse colon, which is an
extremely rare combination.Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
Fig. 2. Tumor marker follow-up data during disease course shown in Graph 1.
Fig. 3. Left supraclavicular lymph node lesion.
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A 67-year-old female patient was diagnosed with gastric signet
ring cell carcinoma, pT2N0M0, status post subtotal gastrectomy in
November 1997. Then she was diagnosed with a second primary
malignancy, left breast cancer, invasive lobular carcinoma,
pT2N2M0, estrogen receptor (ER) 2þ, progesterone receptor (PR)
2þ, status post left modiﬁed radical mastectomy in February 2003,
followed by adjuvant chemotherapy with CEF regimen (cyclo-
phosphamide, epirubicin and 5-ﬂuouracil) and adjuvant hormone
therapy with tamoxifen for ﬁve years. In January 2005, the patient
was diagnosed with a third primary neoplasm, proximal transverse
colon cancer, moderately differentiated adenocarcinoma, Dukes'
stage C2, and underwent status post right hemicolectomy in
November 2005; this was followed by adjuvant chemotherapy with
mFOLFOX-6 regimen (5-ﬂuouracil, leucovorin and oxaliplatin).
However, after the ﬁrst cycle of mFOLFOX-6 regimen, she switched
to capecitabine due to an allergic reaction to oxaliplatin.
The patient then achieved disease-free status as noted in a series
of routine image studies during regular follow-up at our oncology
clinic. In November 2011, she presented due to hematuria for
several days. Diagnostic cystoscopy showed a mass lesion on the
urinary bladder. Whole body computed tomography (CT) scan
revealed an isolated 2.6  2 cm tumor in the right posterior lateral
wall of the urinary bladder (Fig. 1). Cystoscope-assisted biopsy
showed a poorly differentiated adenocarcinoma with signet ring
appearance arising from the submucosa of the urinary bladder. A
metastatic cancer rather than primary urinary bladder cancer was
impressed according to microscopic morphology of tumor and
intact mucosa of urinary bladder. Immunohistochemical (IHC)
proﬁles of the urinary bladder tumor revealed the expression
pattern as CK7þ, CK20þ, CDX2, ER and scattered expression of
PR. Colon origin was excluded due to different morphologic
appearance and IHC proﬁles comparing to previous colon cancer
specimen, which had strong CDX-2 expression. Recurrent breast
cancer was found to be unlikely due to different ER and PR
expression patterns compared to the primary breast cancer.
Under the preliminary diagnosis of recurrent gastric cancer with
solitary urinary bladder metastasis, she received palliative
chemotherapy with weekly high-dose 5-ﬂuorouracil followed by
radiotherapy (5040 centi-Gray divided into 28 fractions) for the
isolated metastatic tumor. Complete tumor response was achieved
and there was no evidence of residual tumor by subsequent tumor
marker (Fig. 2) and imaging follow-up. The patient experienced
abdominal distension and bilateral leg edema in September 2013. A
subsequent CT scan showed multiple metastatic lymph nodes over
para-aortic areas (Fig. 3). Palliative chemotherapy with
docetaxel þ cisplatin regimen was administered as a second line
palliative chemotherapy for recurrent gastric cancer with lymphFig. 1. A 2.6  2 cm tumor in the right posterior lateral wall of urinary bladder.node metastasis based on previous urinary bladder tumor scenario.
Nevertheless, in May 2014, she complained of progressive enlarged
left neck lymph nodes within half a year. Images showed the tumor
had progressed with multiple lymph nodes metastases mainly
involving left supra-clavicle, and mediastinum areas. The patient
received neck lymph node biopsy because of the bizarre growth
rate of her neck lymph node, and the pathologic report conﬁrmed
metastatic carcinoma. However, the microscopic appearance and
IHC proﬁles of neck lymph node tumor were distinct to the urinary
bladder tumor. A complementary pathologic review for a series of
tumors in this patient is mandatory to conﬁrm the origin of met-
astatic neck tumor, and to provide important guidance to best
choose further chemotherapeutic regiments.3. Pathologic ﬁnding
We reviewed specimens microscopically and immunohis-
tochemically with a pathologist, and the urinary bladder lesion
disclosed signet ring cell appearance (Fig. 1) with CK7 (þ). We
preliminarily determined that the cancer had originated from the
stomach. However, in the following lymph node lesion, we
compared samples of these recurrent lymph nodes with original
gastric, breast and colon cancer tissue. Microscopically, lymph node
tissue showed compact sheets and nests of carcinomatous cells
displaying round nuclei, distinct nucleoli and pink cytoplasm
without obvious ductal or glandular structure. IHC stain showed ER
(6F11) (faint þ), PR (1A6) (), CDX2 (), CK20 (þ), CK7 (þ) and
HER-2-neu(polyclone): negative (1þ) (shown in Fig. 4A). Tracing
back previous pathologic reports from gastric, breast and colon
cancer, gastric tissue disclosed signet ring cells and some poorly
differentiated cells scattered microscopically. IHC stain showed ER
(), PR (), Her2 (), CK7 (þ), CK20 (þ, partial) and CDX2 ()
(shown in Fig. 1). The patient's breast tissue revealed poorly
differentiated cells diffusely inﬁltrating into the ﬁbrous stroma and
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100%), PR (þþ, 100%), HER-2-NEU (þþ, 100%), CK7 (þ), CK20 ()
and CDX2 () (shown in Fig. 4B). IHC stains from breast,
gastric, urinary bladder and lymph node tissuewere summarized in
Table 1. The colon cancer presented in cribriform appearance with
moderately glandular differentiation. Morphologically, colon can-
cer as the originating site was initially excluded. Due to the
ambiguous result comparing lymph node tissue with gastric and
breast tissue, we checked further breast cancer-speciﬁc IHC stain e
GCDFP-15 (gross cystic disease ﬂuid protein-15), which showed a
positive predicted value for breast cancer up to 99%.6 In this case,
GCDFP was both positive at breast and lymph node tissue.
Furthermore, we traced back to the urinary bladder pathologic
specimen, which also showed GCDFP-15(þ). Thereafter, we over-
ruled our previous conclusion based upon this new information.
The lymph node and previous urinary bladder lesions were both
favored to be of breast cancer origin. Clinically, CK7þ/CK20þ can be
observed in approximately 11% of breast cancer cases,7 and the new
evidence supported our ﬁnal diagnosis.
4. Discussion
We herein have reported a case of a 67-year-old woman pre-
senting with metastatic carcinoma harboring signet ring cell pic-
ture involving urinary bladder, and later suffered from progressive
lymph node metastasis with underlying triple primary cancers
including gastric, breast and colon cancer. The case reported met
the MPN criteria mentioned above, and presented each tumor with
the interval of more than 1 year, indicating that they were meta-
chronous triple PMNs. Recurrent gastric cancer with bladder
metastasis was diagnosed according to microscopic ﬁndings and
IHC proﬁles expression. Later, due to multiple neck lymph nodes
that progressed despite anti-cancer treatment, we arranged neck
lymph node biopsy and subsequent complementary pathologic
study adjusted our ﬁnal diagnosis to recurrent breast cancer with
eventual lymph node metastasis.
Over the past two decades, the incidence of second primary
malignancy has progressively risen among cancer survivors and is
an issue of increasingly greater concern in oncology. The increasing
incidence may be due to the elevated rate of early cancer detection,
improved cancer treatment and better supportive care with longer
survivor life expectancy. The synchronous occurrence of multiple
cancers, although rare, has been reported sporadically in the pre-
vious literature.8e11 Our own data from a single Taiwan cancer
center institute (Chang Gung Memorial Hospital, CGMH, Taoyung,
Taiwan) showed that from 2002 to 2012,1413 patients (0.64%) were
diagnosed with triple primary cancers and 305 patients (0.13%)
were diagnosedwithmultiplemalignancies of more than 3 cancers.
From our data, a total of 7825 patients were diagnosed with gastric
cancer and 14,941 patients were diagnosed with breast cancer in
the same period of time. Among those gastric cancer patients, 534
patients (6.8%) had second primary cancers, including 100 patients
(1.28%) with colon cancer and 11 patients (0.14%) with breast cancer
as a second primary neoplasm. Among breast cancer patients, 1437
patients (9.6%) had second primary cancer, including 52 patients
(3.5%) with cervical cancer and 47 patients (3.1%) with colon cancerFig. 4. A. Microscopic appearance of three primary malignancies including stomach,
breast and colon, compared with bladder and lymph node lesions. B. IHC stain for
further differentiation In these 3 pictures, we compared ER, GCDFP-15 and cytokeratin
20 (CK20) manifestations in gastric, breast, bladder and lymph node tissues separately
for clariﬁcation of recurrence tissue origin. (a) Both breast and lymph node tissues
showed ER (þ), but not gastric and bladder tissue. (b) Breast, lymph node and bladder
tissues all disclosed breast cancer-speciﬁc marker, GCDFP-15, positive, except gastric
cancer. (c) Both gastric, lymph node tissue and bladder tissue all revealed CD20 (þ).
Table 1
Summary of IHC stain between gastric, breast, urinary bladder and lymph node tissues.
ER PR Her2/neu Mammoglobin GCDFP-15 CK7 CK20 CDX2
Stomach      þ
Moderate
þ
Focal faint

Breast 2þ
Faint
2þ 2þ  þ
Focal faint
þ
Strong
þ
Focal faint

Urinary bladder  
Focal, <1%
2þ
FISH ()
 þ
Focal faint
þ
Strong
þ
Focal faint

LN þ
2%, Faint
 1þ
5%, Faint
 þ
Focal faint
þ
Strong
þ
Strong

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registry). Therefore, cases with triple primary malignancies are
extremely rare. Therefore, the limited knowledge to be derived
from such a rare experience contributes to the challenge upon
clinical diagnosis despite detailed history-taking, physical exami-
nation, thorough imaging check-up and advanced immunohisto-
chemical stain techniques. Yet knowledge gained from these rare
cases, however limited, may aid in the diagnosis of future cases.
Clinically, we observed typically multicentric tumors involved
with shared risk factor exposure and/or genetic predispositionwith
the phenomenon called “ﬁeld cancerization”, especially in the head
and neck area, and colorectal and urinary tract cancers. Conversely,
the situation of multiple tumors involving diverse sites commonly
has occurred by coincidence; however, it is also possible that ﬁeld
cancerization plays a role in their development. In addition,
chemotherapy and radiotherapy may also contribute to the devel-
opment of neoplasms, such as secondary leukemia and
sarcoma.12,13
Hereditary cancer syndrome accounts for only 5% of all malig-
nancies and usually presents with the following characteristics: 1)
strong family history with high penetrance genotypes, such as
hereditary breast and ovarian cancer syndrome with BRCA-1 gene
and familial adenomatous polyposis with FAP gene; 2) multiple
primary cancers with or without speciﬁc tissue type, such as Li-
Fraumeni syndrome with early onset sarcoma, adrenocortical car-
cinoma, brain tumor, leukemia or premenopausal breast cancer;
hereditary diffuse gastric cancer with diffuse gastric cancer and
invasive lobular breast carcinoma; 3) unusual clinical presentation,
such as early onset in hereditary diffuse gastric cancer, Lynch
syndrome, and FAP (or multicentric tumors with Von Hippel-
Lindau syndrome, heritable retinoblastoma, FAP); or 4) associated
non-malignant disease, such as mucocutaneous pigmentation in
Peutz-Jeghers syndrome or ataxia telangiectasia with cerebellar
ataxia, telangiectasia, or vitiligo.14e16
In Taiwan, breast cancer is the most prevalent type of cancer for
females, with up to 10% of the breast cancers associated with spe-
ciﬁc hereditary mutations in single-acting genes.17 Hereditary
breast cancer may be present with the following syndromes: he-
reditary breast and/or ovarian cancer syndrome (HBOC syndrome)
linked tomutation in BRCA1 or BRCA2 gene; Li-Fraumeni syndrome
with a germline TP53 gene mutation; and Cowden syndrome/PTEN
hamartoma syndrome, an autosomal disorder associated with
germline mutations in the PTEN tumor suppressor gene.18e20 There
are some additional genetic mutations associated with breast/
ovarian cancer risk, such as CDH1 gene noted in hereditary diffuse
gastric cancer syndrome, STK11/LKB1 gene shown in Peutz-Jeghers
syndrome, and MMR (Mismatch repair) gene including MLH1,
MSH2, MSH6 and PMS2 or EPCAM gene deletion expressed in
Lynch syndrome.21e23 According to the National Comprehensive
Cancer Network (NCCN) guidelines, the criteria for which further
genetic risk evaluation should be considered in breast cancer pa-
tients includes a known mutation in a breast cancer susceptibilitygene within the family, early-age-onset breast cancer, triple nega-
tive (ER-, PR-, Her2-) breast cancer, two breast cancer primaries in a
single individual, invasive ovarian cancer, male breast cancer, and
breast cancer at any age with a)  1 close blood relative with breast
cancer at  50 years of age; b)  1 close blood relative with ovarian
cancer at any age; c)  2 close blood relative with breast cancer
and/or pancreatic cancer at any age; d) combination of 1 of the
following malignancies: pancreatic cancer, prostate cancer (Glea-
son score S 7), sarcoma, adrenocortical carcinoma, brain tumors,
endometrial cancer, thyroid cancer, kidney cancer, hamartomatous
polyps of the gastrointestinal tract, and diffuse gastric cancer.24
Hereditary syndromes with increased risk for gastric cancer
include: 1) hereditary diffuse gastric cancer, 2) Lynch syndrome/
hereditary non-polyposis colorectal cancer, 3) juvenile polyposis
syndrome, 4) Peutz-Jeghers syndrome and 5) familial adenomatous
polyposis. Hereditary diffuse gastric cancer (HDGC) is an autosomal
dominant syndrome characterized by the development of diffuse
(signet ring cell) gastric cancers at a young age.25 Mutation of the
CDH1 gene (the gene encoding the cell adhesion molecular E-
cadherin) mutation noted in 30e50% of gastric cancer patients.26
The lifetime cumulative risk in CDH1 mutation carriers to
develop gastric cancer is estimated at 67% for men and 83% for
women by the age of 80 years, and the risk of developing lobular
breast cancer inwomen is up to 60% by age 80.25,27 According to the
NCCN guidelines, cases meeting any the following criteria should
undergo further risk assessment and genetic evaluation: a) a
known mutation in a gastric cancer susceptibility gene within the
family, b) early-age-onset gastric cancer (<50 years of age), c) a
diffuse gastric cancer occurring before age 40 years, d) personal or
family history of diffuse gastric cancer and lobular gastric cancer,
one diagnosed before age 50 years, e) two gastric cancer cases in
family, one individual under age 50 years with conﬁrmed diffuse
gastric cancer, and f) three conﬁrmed diffuse gastric cancer cases in
ﬁrst and second degree relatives independent of age.24
Syndromes linked to genetic susceptibility to colorectal cancer
are: (1) familial adenomatous polyposis (FAP), (2) Lynch syndrome/
hereditary non-polyposis colorectal cancer (HNPCC), (3) MUTYH-
associated polyposis, and then some less common syndromes
such as Tuir-Torre, Turcot, Gardner, Cowden, Bannayan-Riley-
Ruvalcaba, Peutz-Jeghers, juvenile polyposis, and serrated polypo-
sis syndromes. Colorectal cancer screening is recommended for
those patients with a higher potential for inherited colon cancer.
Speciﬁc clinical features associated with different genetic mu-
tations as well as familial history and other risk factors may provide
hints for the diagnosis of hereditary cancers. In our case, the patient
was diagnosed with gastric cancer, then left breast invasive lobular
carcinoma and later proximal transverse colon cancer. Pathological
review revealed that the urinary bladder was impressed as being
gastric in origin with signet ring cell appearance morphologically;
but later, a different pathological expression of lymph node lesions
showed positive breast cancer-speciﬁc marker expression (GCDFP-
15). As a result, breast cancer origin was favored. These ﬁndings
C.-Y. Hung et al. / Journal of Cancer Research and Practice 3 (2016) 49e53 53together with the patient's triple primarymalignancy diagnosis, led
to the suspicion of a hereditary syndrome.
Further genetic study for CDH1 gene, STK11/LKB1 gene, EPCAM
gene deletion or MMR gene, including MLH1, MSH2, MSH6 and
PMS2 are appropriate for evaluation of hereditary gastric cancer
with breast cancer occurrence or STK11/LKB1 gene. Unfortunately,
the patient expired before further evaluation could be performed,
and we were not able to conduct genetic testing for a deﬁnitive
conﬁrmation. However, according to the patient's clinical course
and disease behavior, diffuse gastric cancer, breast cancer and
colorectal cancer were concluded to be the patient's functional
disease combination.Conﬂict of interest
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